GNMSF.US Genmab A/S

Healthcare Biotechnology USA Stocks
509.50 USD
Close of Nov 14, 2026
232.34 581.00
Market cap
USD 31.4B
P/E
43.5x
P/B
4.96x
ROE
14.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is GNMSF.US undervalued?

Graham number

The Graham number of Genmab A/S cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Genmab A/S fundamental analysis

No fundamental analysis for Genmab A/S yet.

Genmab A/S stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Genmab A/S

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also develop…

Full company profile